REFERENCES

 
  1. Lindahl, U., Lidholt, K., Spillmann, D. and Kjellen, L. (1994) More to "heparin" than anticoagulation. Thromb. Res. 75, 1-32.
  2. Maccarana, M. (1994) O-sulfate groups in heparin and heparan sulfate. Formation and roles in protein binding. Ph. D. Dissertation Thesis. Acta Universitatis Upsaliensis, Uppsala, Sweden.
  3. Doolittle, R. F. (1992) Reconstructing history with amino acid sequences. Protein Sci. 1, 191-200.
  4. Stipp, C. S., Litwack, E. D. and Lander, A. D. (1994) Cerebroglycan: an integral membrane heparan sulfate proteoglycan that is unique to the developing nervous system and expressed specifically during neuronal differentiation. J. Cell Biol. 124, 149-160.
  5. Massaguè, J. (1992) Receptors for the TGF-beta family. Cell 69, 1067-1070.
  6. Brown, T. A., Bouchard, T., St John, T., Wayner, E. and Carter, W. G. (1991) Human keratinocytes express a new CD44 core protein (CD44E) as a heparan sulfate intrinsic membrane proteoglycan with additional exones. J. Cell Biol. 113, 207-221.
  7. Bernfield, M., Kokenyesi, R., Kato, M., Hinkes, M. T., Spring, J., Gallo, R. L. and Lose, E. J. (1992) Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu. Rev. Cell Biol. 8, 165-193.
  8. Lopez-Casillas, F., Cheifetz, S., Doody, J., Andres, J. L., Lane, W. S. and Massague, J. (1991) Structure and expression of the membrane proteoglycan betaglycan, a component of the TGF-b receptor system. Cell 67, 785-795.
  9. Hayashi, K., Madri, J. A. and Yurchenco, P. D. (1992) Endothelial cells interact with the core protein of basement membrane perlecan through b1 and b3 integrins: an adhesion modulated by glycosaminoglycans. J. Cell Biol. 119, 945-959.
  10. Lowe-Krentz, L. J., Thompson, K. and Patton II, W. A. (1992) Heparin releasable and nonreleasable forms of heparan sulfate proteoglycan are found on the surfaces of cultured porcine aortic endothelial cells. Mol. Cell. Biochem. 109, 51-60.
  11. Saksela, O., Moscatelli, D., Sommer, A. and Rifkin, D. B. (1988) Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J. Cell Biol. 107, 743-751.
  12. Bashkin, P., Doctrow, S., Klagsbrun, M., Svahn, C. M., Folkman, J. and Vlodavsky, I. (1989) Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 28, 1737-1743.
  13. Brunner, G., Gabrilove, J., Rifkin, D. B. and Wilson, E. L. (1991) Phospholipase C release of basic fibroblast growth factor from human bone marrow cultures as a biologically active complex with a phosphatidylinositol-anchored heparan sulfate proteoglycan. J. Cell Biol. 114, 1275-1283.
  14. Fedarko, N. S. and Conrad, E. (1986) A unique heparan sulfate in the nuclei of hepatocytes: structural changes with the growth state of the cells. J. Cell Biol. 102, 587-599.
  15. Kanwar Y. S. and Farquhar, M. G. (1979). Presence of heparan sulfate in the glomerular basement membrane. Proc. Natl. Acad. Sci. U.S.A. 76, 1303-1307.
  16. Castellot, J. J. Jr, Addonizio, M. L., Rosenberg, R. and Karnovsky, M. J. (1981) Cultured endothelial cells produce a heparinlike inhibitor of smooth muscle cell growth. J. Cell Biol. 90, 372-379.
  17. Marcum, J. A., McKenney, J. B. and Rosenberg, R. D. (1984) Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparin-like molecules bound to the endothelium.. J Clin. Invest. 74, 341-350.
  18. Williams, M. P., Steeter, H. B., Wusteman, F. S. and Cryer, A. (1983) Heparan sulfate and the binding of lipoprotein lipase to porcine thoracic aorta endothelium. Biochem. Biophys. Res. Commun. 756, 83-91.
  19. Danielsson, A., Raub, E., Lindahl, U. and Bjork, I. (1986) Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa. J. Biol. Chem. 261, 15467-15473.
  20. Kramer, R. H., Voegel, K. G. and Nicolson, G. L. (1982) Solubilization and degradation of subendothelial matrix glycoproteins and proteoglycans by metastatic tumor cells. J. Biol. Chem. 257, 2678-2686.
  21. Oohira, A., Wight, T. N. and Bornstein, P. (1983) Sulfated proteoglycans synthesized by vascular endothelial cells in culture. J. Biol. Chem. 258, 2014-2021.
  22. Busch, P. C. (1984) Sulfated glycosaminoglycans and vascular endothelial cells, in Biology of endothelial cells (Jaffe, E., ed.) Martinus Nijhoff Publisher, Boston, pp. 178-188.
  23. Kojima, T., Leone, C. W., Marchildon, G. A., Marcum, J. A. and Rosenberg, R. D. (1992) Isolation and characterization of heparan sulfate proteoglycans produced by cloned rat microvascular endothelial cells. J. Biol. Chem. 267, 4859-4869.
  24. Kojima, T, Shworak, N. W. and Rosenberg, R. D. (1992) Molecular cloning and expression of two distinct cDNA-encoding heparan sulfate proteoglycan core proteins from a rat endothelial cell line. J. Biol. Chem. 267, 4870-4877.
  25. Kojima, T., Katsumi, A., Yamazaki, T., Muramatsu, T., Nagasaka, T., Ohsumi, K. and Saito, H. (1996) Human ryudocan from endothelium-like cells binds basic fibroblast growth factor, midkine, and tissue factor pathway inhibitor. J. Biol. Chem. 271, 5914-5920.
  26. Saksela, O. and Rifkin, D. B. (1990). Release of basic fibroblast growth factor-heparan sulfate complexes from endothelial cells by plasminogen activator-mediated proteolytic activity, J. Cell Biol. 110, 767-775.
  27. Lose, E. and Bernfield, M. (1991) Pulmonary artery endothelial cells produce syndecan, a cell surface proteoglycan and possible low-affinity bFGF receptor. J. Cell Biol. 115, 417a.
  28. Avezier, D., Hecht, D., Safran, M., Elsinger, M., David, G. and Yayon, A. (1994) Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 79, 1005-1013.
  29. Kinsella, M. G. and Wight, T. N. (1988) Structural characterization of heparan sulfate proteoglycan subclasses isolated from bovine aortic endothelial cell cultures. Biochemistry 27, 2136-2144.
  30. Marcum, J. A. and Rosenberg, R. D. (1985) Heparin-like molecules with anticoagulant activity are synthesized by cultured endothelial cells. Biochem. Biophys. Res. Commun. 126, 365-372.
  31. Sasisekharan, R., Moses, M., Nugent, M. A., Cooney, C. L. and Langer, R. (1994) Heparinase inhibits neovascularization. Proc. Natl. Acad. Sci. U.S.A. 91, 1524-1528.
  32. Mali, M., Elenius, K., Miettinen, H. M. and Jalkanen, M. (1993) Inhibition of basic fibroblast growth factor-induced growth promotion by overexpression of syndecan-1. J. Biol. Chem. 268, 24215-24222.
  33. Samivirta, M., Heino, J. and Jalkanen, M. (1992) Basic fibroblast growth factor-syndecan complex at cell surface or immobilized to matrix promotes cell growth. J. Biol. Chem. 267, 17606-17610.
  34. Avezier, D., Levy, E., Safran, M., Svahn, C., Buddeke, E., Shmidt, E., David, G., Vlodavsky, I. and Yayon, A. (1994) Differential structural requirements of heparin and heparan sulfate proteoglycans that promote binding of basic fibroblast growth factor to its receptor. J. Biol. Chem. 269, 114-121.
  35. Coltrini, D., Rusnati, M., Zoppetti, G., Oreste, P., Grazioli, G., Naggi, A. and Presta, M. (1994) Different effects of mucosal, bovine lung and chemically modified heparin on selected biological properties of basic fibroblast growth factor. Biochem. J., 303, 583-590.
  36. Gospodarowicz, D., and Cheng, J. (1986) Heparin protects basic and acidic FGF from inactivation. J. Cell. Physiol. 128, 175-184.
  37. Sommer, A., and Rifkin, D. B. (1989) Interaction of heparin with human basic fibroblast growth factor: protection of the angiogenic protein from proteolytic degradation by a glycosaminoglycan. J. Cell. Physiol. 138, 215-220.
  38. Flaumenhaft, R., Moscatelli, D. and Rifkin, D. B. (1990) Heparin and heparan sulfate increase the radius of diffusion and action of basic fibroblast growth factor. J. Cell Biol. 111, 1651-1659.
  39. Flaumenhaft, R., Moscatelli, D., Saksela, O. and Rifkin, D. B. (1989) Role of extracellular matrix in the action of basic fibroblast growth factor: matrix as a source of growth factor for long-term stimulation of plasminogen activator production and DNA synthesis. J. Cell. Physiol. 140, 75-81.
  40. Presta, M., Maier, J. A. M., Rusnati, M. and Ragnotti, G. (1989) Basic fibroblast growth factor is released from endothelial extracellular matrix in a biologically active form. J. Cell. Physiol. 140, 68-74.
  41. Rogelj, S., Klagsbrun, M., Atzmon, R., Kurokawa, M., Haimovitz, A., Fuks, Z. and Vlodavsky, I. (1989) Basic fibroblast growth factor is an extracellular matrix component required for supporting the proliferation of vascular endothelial cells and the differentiation of PC12 cells. J. Cell Biol. 109, 823-831.
  42. Nugent, M. A. and Edelman, E. R. (1992) Transforming growth factor b1 stimulates the production of basic fibroblast growth factor binding proteoglycans in Balb/c3T3 cells. J. Biol. Chem. 267, 21256-21264.
  43. Elenius, K., Maata, A., Salmivirta, M. and Jalkanen, M. (1992) Growth factors induce 3T3 cells to express bFGF-binding syndecan. J. Biol. Chem, 267, 6435-6441.
  44. Ausprunk, D. H., Boudreau, C. L. and Nelson, D. A. (1981) Proteoglycans in the microvasculature. Histochemical localization in microvessel of the rabbit eye. Am. J. Pathol. 103, 353-366.
  45. Ausprunk, D. H. (1982) Synthesis of glycoproteins by endothelial cells in embryonic blood vessels. Dev. Biol. 90, 79-90.
  46. Montesano, R., Mossaz, A., Ryser, J.-E., Oril, L. and Vassalli, P. (1984) Leukocyte interleukines induce cultured endothelial cells to produce a highly organized, glycosaminoglycan-rich pericellular matrix. J. Cell Biol. 99, 1706-1715.
  47. Spillmann, D. and Lindahl, U. (1994) Glycosaminoglycan-protein interactions. A question of specificity. Curr. Opin. Struct.. Biol. 4, 677-682.
  48. Yamaguchi, Y., Mann, D. M., and Ruoslahti, E. (1990) Negative regulation of transforming growth factor-b by the proteoglycan decorin. Nature (Lond.) 346, 281-284.
  49. Ruoslahti, E. and Yamaguchi, Y. (1991) Proteoglycans as modulator of growth factor activities. Cell 64, 867-869.
  50. Rusnati, M., Urbinati, C. and Presta, M. (1993) Internalization of basic fibroblast growth factor (bFGF) in cultured endothelial cells: role of the low affinity heparin-like bFGF receptors. J. Cell. Physiol. 154, 152-161.
  51. Revis-Gupta, S., Abdel-Ghany, M., Koland, J. and Racker, E. (1991) Heparin stimulates epidermal growth factor receptor-mediated phosphorylation of tyrosine and threonine residues. Proc. Natl. Acad. Sci. U.S.A. 88, 5954-5958.
  52. Gao, G. and Goldfarb, M. (1995) Heparin can activate a receptor tyrosine kinase. EMBO J. 14, 2183-2190.
  53. Chernousov, M. A. and Carey, D. J. (1993). N-syndecan (syndecan-3) from neonatal rat brain binds basic fibroblast growth factor. J. Biol. Chem, 268, 16810-16814.
  54. Andres, J. L., DeFalcis, D., Noda, M. and Massague, J. (1992) Binding of two growth factor families to separate domains of the proteoglycan betaglycan. J. Biol. Chem. 267, 5927-5930.
  55. Nurcombe, V., Ford, M. D., Wildschut, J. A. and Bartlett, P. F. (1995). Developmental regulation of neuronal response to FGF-1 and FGF-2 by heparan sulfate proteoglycan. Science 260, 103-106.
  56. Bernfield, M. and Sanderson, R. D. (1990) Syndecan, a developmentally regulated cell surface proteoglycan that binds extracellular matrix and growth factors. Phil. Trans. R. Soc. Lond., 327, 171-186.
  57. Maccarana, M., Casu, B. and Lindahl, U. (1993) Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J. Biol. Chem, 268, 23898-23905.
  58. Guimond, S., Maccarana, M., Olwin, B. B., Lindahl, U. and Rapraeger, A. C. (1993) Activating and inhibitory heparin sequences for FGF-2 (basic FGF). Distinct requirements for FGF-1, FGF-2, and FGF-4. J. Biol. Chem. 268, 23906-23914.
  59. Lyon, M. and Gallagher, J. T. (1994) Hepatocyte growth factor/scatter factor: a heparan sulphate-binding pleiotropic growth factor. Biochem. Soc. Trans. 22, 365-370.
  60. Rusnati, M., Coltrini, D., Oreste, P., Zoppetti, G., Albini, A., Noonan, D., d'Adda di Fagagna, F., Giacca, M. and Presta, M. Interaction of HIV-1 Tat protein with heparin. J. Biol. Chem. 272, in press.
  61. Ishihara, M., Shaklee, P. N., Yang, Z., Liang, W., Wei, Z., Stack, R. J. and Holme, K. (1994) Structural features in heparin which modulate specific biological activities mediated by basic fibroblast growth factor. Glycobiol. 4, 451-458.
  62. Ornitz, D. M., Herr, A. B., Nilsson, M., Westman, J., Svahn, C. M. and Waksman, G. (1995) FGF binding and FGF receptor activation by synthetic heparan-derived di- and trisaccharides. Science 268, 432-436.
  63. Baird, A., Schubert, D., Ling, N. and Guillemin, R. )1988) Receptor- and heparin-binding domains of basic fibroblast growth factor Proc. Natl. Acad. Sci. U.S.A. 85, 2324-2328.
  64. Seno, M., Sasada, R., Kurokawa, T. and Igarashi, K. (1990) Carboxyl-terminal structure of basic fibroblast growth factor significantly contributes to its affinity for heparin. Eur. J. Biochem. 188, 239-245.
  65. Li, L., Safran, M., Aviezer, D., Bohlen, P., Seddon, A. P. and Yayon, A. (1994) Diminished heparin binding of a fibroblast growth factor mutant is associated with reduced receptor binding, mitogenesis, plasminogen activator induction, and in vitro angiogenesis. Biochemistry 33, 10999-11007.
  66. Zhang, J., Cousens, L. S., Barr, P. J. and Sprang, S. R. (1991) Three-dimensional structure of human basic fibroblast growth factor, a structural homologue of interleukin 1b.Proc. Natl. Acad. Sci. U.S.A. 88, 3446-3450.
  67. Zhu, X., Komiya, H., Chirino, A., Faham, S., Fox, G. M., Arakawa, T., Hsu, B. T. and Rees, D. C. (1990). Three-dimensional structures of acidic and basic fibroblast growth factors, Science 251, 90-93.
  68. Eriksson, A. E., Cousens, L. S., Weaver, L. H. and Matthews, B. W. (1991) Three-dimensional structure of human basic fibroblast growth factor. Proc. Natl. Acad. Sci. U.S.A. 88, 3441-3445.
  69. Thompson, L. D., Pantoliano, M. W. and Springer, B. A. (1994) Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. Biochemistry 33, 3831-3840.
  70. Kennet, A. T. (1996) Vascular endothelial growth factor, a potent and selective angiogenic agent. J. Biol. Chem. 271, 603-606.
  71. Chang, H. C., Samaniego, F., Nair, B. C., Buonaguro, L. and Ensoli, B. (1997) HIV-Tat protein exits from intact cells through a leaderness secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans. submitted
  72. Baird, A. and Ling, N. (1987) Fibroblast growth factors are present in the extracellular matrix produced by endothelial cells in vitro: implications for a role of heparinase-like enzymes in the neovascular response. Biochem. Biophys. Res. Commun. 142, 428-435.
  73. Vlodavsky, I., Folkman, J., Sullivan, R., Fridman, R., Ishai-Michaeli, R., Sasse, J. and Klagsbrun, M. (1987) Endothelial cell-derived basic fibroblast growth factor: synthesis and deposition into subendothelial extracellular matrix. Proc. Natl. Acad. Sci. U.S.A. 84, 2292-2296
  74. Folkman, J., Klagsbrun, M., Sasse, J., Wadzinsky, M., Ingber, D. and Vlodavsky, I. (1988) A heparin-binding angiogenic protein - basic fibroblast growth factor - is stored within basement membrane. Am. J. Pathol. 130, 393-400.
  75. DiMario, J., Buffinger, N., Yamada, S. and Strohman, R. C. (1989) Fibroblast growth factor in the extracellular matrix of dystrophic (mdx) mouse muscle. Science 244, 688-690.
  76. Hageman, G. S., Kirchoff-Rempe, M. A., Lewis, G. P., Fisher, S. K. and Anderson, D. H. (1991) Sequestration of basic fibroblast growth factor in the primate retinal interphotoreceptor matrix. Proc. Natl. Acad. Sci. U.S.A. 88, 6706-6710.
  77. Rusnati, M. and Presta, M. (1996) Interaction of angiogenic basic fibroblast growth factor with endothelial cell heparan sulfate proteoglycans. Int. J. Clin. Lab. Res. 26, 15-23.
  78. Ingber, D. E., and Folkman, J. (1989) Mechano-chemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: role of extracellular matrix. J. Cell Biol. 109, 317-330.
  79. Vlodavsky, I., Bar-Shavit, R., Ishai-Michaeli, R., Bashkin, P. and Fuks Z. (1991) Extracellular sequestration and release of fibroblast growth factor: a regulatory mechanism? Trends Biol. Sci. 16, 268-271.
  80. Tamura, T., Nakanishi, T., Kimura, Y., Hattori, T., Sasaki, K., Norimatsu, H., Takahashi, K. And Takigawa, M. (1996) Nitric oxide mediates interleukin-1-induced matrix degradation and basic fibroblast growth factor release in cultured rabbit articular chondrocytes: a possible mechanism of pathological neovascularization in arthritis. Endocrinology 137, 3729-3737.
  81. Mustonen, T. and Alitalo, K. (1995) Endothelial receptor tyrosine kinases involved in angiogenesis. J. Biol. Chem. 129, 895-898.
  82. Rapraeger, A. C., Krufka, A. and Olwin, B. B. (1991) Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation. Science 252, 1705-1708.
  83. Gitay-Goren, H., Soker, S., Vlodavsky, I. and Neufeld, G. (1992) The binding of vascular endothelial growth factor to its receptor is dependent on cell surface-associated heparin-like molecules. J. Biol. Chem. 267, 6093-6098.
  84. Yayon, A., Klagsbrun, M., Esko, J. D., Leder, P. and Ornitz, D. M. (1991) Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell 64, 841-848.
  85. Roghani, M., Mansukhani, A., Dell'Era, P., Bellosta, P., Basilico, C., Rifkin, D. B. and Moscatelli, D. (1994) Heparin increase the affinity of basic fibroblast growth factor for its receptor but is not required for binding. J. Biol. Chem. 269, 3927-3984.
  86. Ornitz, D. M., Yayon, A., Flanagan, J. G., Svahn, C. M., Levi, E. and Leder, P. (1992) Heparin is required for cell-free binding of basic fibroblast growth factor to a free receptor and for mitogenesis in whole cells. Mol. Cell. Biol. 12, 240-247.
  87. Rusnati, M., Coltrini, D., Caccia, P., Dell'Era, P., Zoppetti, G., Oreste, P., Valsasina, B. and Presta, M. (1994) Distinct role of 2-O-, N-, and 6-O-sulfate groups of heparin in the formation of the ternary complex with basic fibroblast growth factor and soluble FGF receptor-1. Biochem. Biophys. Res. Commun. 203, 450-458.
  88. Tessler, S., Rockwell, P., Hicklin, D., Cohen, T., Levi, B.-Z., Witte, L., Lemischka, I.R. and Neufeld, G. (1994) Heparin modulates the interaction of VEGF165 with soluble and cell associated flk-1 receptors. J. Biol. Chem. 269, 12456-12461.
  89. Choen, T., Gitay-Goren, H., Sharon, R., Shibuya, M., Halaban, R., Levi, B.-Z. and Neufeld, G. (1995) VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells. J. Biol. Chem. 270, 11322-11326.
  90. Turnbull, J. E. and Gallagher, J. T. (1993) Heparan sulfate: functional role as modulator of fibroblast growth factor activity. Biochem. Soc. Transact. 21, 477-482.
  91. Kan, M., Wang, F., Xu, J., Crabb, J. W., Hou, J. and McKeehan, L. W. (1993) An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 259, 1918-1921.
  92. Ishihara, M., Tyrrell, D. J., Stauber, G. B., Brown, S., Cousens, L. S. and Stack, R. J. (1993) Preparation of affinity-fractionated, heparin-derived oligosaccharides and their effects on selected biological activities mediated by basic fibroblast growth factor. J. Biol. Chem. 268, 4675-4683.
  93. Tyrrell, D. J., Ishihara, M., Rao, N., Horne, A., Kiefer, M. C., Stauber, G. B., Lam, L. H. and Stack, R. J. (1993) Structure and biological activities of a heparin-derived hexasaccharides with high affinity for basic fibroblast growth factor. J. Biol. Chem. 268, 4684-4689.
  94. Walker, A., Turnbull, J. E. and Gallagher, J. T. (1994) Specific heparan sulfate saccharides mediate the activity of basic fibroblast growth factor. J. Biol. Chem. 269, 931-935.
  95. Coltrini, D., Rusnati, M., Zoppetti, G., Oreste, P., Isacchi, A., Caccia, P., Bergonzoni, L. and Presta, M. (1993) Biochemical bases of the interaction of human fibroblast growth factor with glycosaminoglycans. Eur. J. Biochem. 214, 51-58.
  96. Ullrich, A. and Schlessinger, J. (1990) Signal transduction by receptors with tyrosine-kinase activity. Cell 61, 203-212.
  97. Spivak-Krolzman, T., Lemmon, M. A., Dikic, I., Ladbury, J. E., Pinchasi, D., Huang, J., Jaye, M., Crumley, G., Schlessinger, J. and Lax, I. (1994) Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell 79, 1015-1024.
  98. Klagsbrun, M. and Baird, A. (1991) A dual receptor system is required for basic fibroblast growth factor activity. Cell 67, 229-31.
  99. Taylor, S. and Folkman, J. (1982) Protamine is an inhibitor of angiogenesis. Nature 297, 307-312.
  100. Neufeld, G. and Gospodarowicz, D. (1987) Protamine sulfate inhibits mitogenic activities of the extracellular matrix and fibroblast growth factor, but potentiates that of epidermal growth factor. J. Cell. Physiol. 132, 287-294.
  101. Baggiolini, M., Dewald, B. and Moser, B. (1994) Interleukin-8 and related chemotactic cytokines - CXC and CC chemokines. Adv. Immunol. 55, 97-179
  102. Mantovani, A., Bussolino, F. and Introna, M. (1997) Cytokine regulation of endothelial cell function: from molecular level to the bed side. Immunol. Today, in press.
  103. Kelner, G. S., Kennedy, J., Bacon, K. B., Kleyensteuber, S., Largaespada, D. A., Jenkins, N. A., Copeland, N. G., Bazan, J. F., Moore, K. W., Schall, T. J. and Zlotnik, A. (1994) Lymphotactin: a cytokine that represents a new class of chemokine. Science 266, 1395-1399
  104. Murphy, P. M. (1996) Chemokine receptors: structure, function and role in microbial pathogenesis. Cytokine & Growth Factors Rev. 1, 47-64
  105. Horuk, R. (1994) The interleukin-8-receptor family - From chemokines to malaria. Immunol. Today 15, 169-174
  106. Witt, D. P. and Lander, A. D. (1994) Differential binding of chemokines to glycosaminoglycan subpopulations. Curr. Biol. 4, 394-400
  107. Rot, A. (1992) Endothelial cell binding of NAP-1/IL-8 role in neutrophil emigration. Immunol. Today 13, 291-294
  108. Strieter, R. M., Polverini, P. J., Kunkel, S. L., Arenberg, D. A., Burdick, M. D., Kasper, J., Dzuiba, J., Van Damme, J., Walz, A., Marriot, D., Chan, S.-Y., Roczniak, S. and Shanafelt, A. B. (1995) The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 270, 27348-27357
  109. Maione, T. E., Gray, G. S., Petro, J., Hunt, A. J., Donner, A. L., Bauer, S. I., Carson, H. F. and Sharpe, R. J. (1990) Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides. Science 247, 77-79
  110. Fan, T.-P. (1994) Angiosuppressive therapy for cancer. Trends Pharmacol. Sci. 15, 33-36.
  111. Staddon, A., Henry, D. and Bonnem, E. (1994) A randomized dose finding study of recombinant platelet factor 4 (rPF4) in cutaneous AIDS-related Kaposi's sarcoma. Proc. Am. Soc. Clin. Oncol. 13, 50.
  112. Luster, A. D., Greenberg, S. M. and Leder, P. (1995) The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J. Exp. Med. 182, 219-231
  113. Watson, J. B., Getzler, S. B. and Mosher, D. F. (1994) Platelet factor 4 modulates the mitogenic activity of basic fibroblast growth factor. J. Clin. Invest. 94, 261-268.
  114. Maione, T. E., Gray, C. S., Hunt, and Sharpe, R. J. (1991) Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity. Cancer Res. 51, 2077-2083.
  115. Cao, Y., Chen, C., Weatherbee, J. A., Tsang, M. and Folkman, J. (1995) Gro-g, a -C-X-C- chemokine, is an angiogenesis inhibitor that suppresses the growth of Lewis lung carcinoma in mice. J. Exp. Med. 182, 2069-2072
  116. Inoue, K., Korenaga, H., Tanaka, N. G., Sakamoto, N. and Kadoya, S. (1988) The sulfated polysaccharide-peptidoglycan complex potently inhibits embryonic angiogenesis and tumor growth in the presence of cortisone acetate. Carbohydr. Res. 181, 135-142.
  117. Nakayama, Y., Iwahana, M., Sakamoto, N., Tanaka, N.G. and Osada, Y. (1993) Inhibitory effects of a bacteria-derived sulfated polysaccharide against basic fibroblast growth factor-induced endothelial cell growth and chemotaxis. J. Cell. Physiol. 154, 1-6.
  118. Chleboun, J. O., Sellers, P., Muir, G., Chew, P. and Martins, R. N. (1994) The effect of tecogalan sodium on the development of the collateral circulation after acute arterial occlusion. Biochem. Biophys. Res. Commun. 202, 1149-1155.
  119. Murata, T., Ishibashi, T., Yoshikawa, H., Khalil, A. and Inomata, H. (1995) Tecogalan sodium inhibits corneal neovascularization induced by basic fibroblast growth factor. Ophthalmol. Res. 27, 330-334.
  120. Sakamoto, T., Ishibashi, T., Kimura, H., Yoshikawa, H., Spee, C., Haris, M. S., Hinton, D. R. and Ryan, S. J. (1995) Effect of tecogalan sodium on angiogenesis in vitro by choroidal endothelial cells. Invest. Ophthalmol. Visual Sci. 36, 1076-1083.
  121. Nakamura, S., Sakurada S., Salahuddin, S. Z., Osada, Y., Tanaka, N. G., Sakamoto, N., Sekiguchi, M. and Gallo R. C. (1992) Inhibition of development of Kaposi's sarcoma-related lesions by a bacterial cell wall complex. Science 255, 1437-1440.
  122. Eckhardt S. G., Burris, H. A.,Eckhardt, J. R., Weiss, G., Rodriguez, G., Rothenberg, M., Rinaldi, D., Barrington, R., Kuhn, J. G., Masuo, K., Sudo, K., Atsumi, R., Oguma, T., Higashi, L., Fields, S., Smetzer, L., Burris, H. and Von Hoff, D. D. (1996) A phase I clinical and pharmacokinetic study of the angiogenesis inhibitor tecogalan sodium. Ann. Oncol. 7, 265-311.
  123. Dennis, P. A., Saksela, O., Harpel, P. and Rifkin, D. B. (1989) a2-Macroglobulin is a binding protein for basic fibroblast growth factor. J. Biol. Chem. 264, 7210-7216.
  124. Socker, S., Svahn, C. M. and Neufeld, G. (1993) Vascular endothelial growth factor is inactivated by binding to a2-macroglobulin and the binding is inhibited by heparin. J. Biol. Chem. 268, 7685-7691.
  125. De Clerque, E. (1987) Suramin in the treatment of AIDS: mechanism of action. Antiviral Res. 7, 1-10.
  126. Hawkins, M. J. (1995) Clinical trials of antiangiogenic agents. Curr. Opin. Oncol. 7, 90-93.
  127. Coffey, R. J., Leof, E. B., Shipley, G. and Moses, H. L. (1987) Suramin inhibition of growth factor receptor binding and mitogenicity in AKR-2B cells. J. Cell. Physiol. 132, 143-148.
  128. Braddock, P. S., Hu, D. E., Fan, T. P., Stratford, I. J., Harris, A. L. and Bicknell, R. (1994) A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions. Brit. J. Cancer 69, 890-898.
  129. Rusnati, M., Dell'Era, P., Urbinati, C., Tanghetti, E., Masardi, M. L., Nagamine, Y., Monti, E. and Presta, M. (1996) A distinct basic fibroblast growth factor (FGF-2)/FGF receptor interaction distinguishes urokinase-type plasminogen activator induction from mitogenicity in endothelial cells. Mol. Biol. Cell. 7, 369-381.
  130. Bojanowski, K., Lelievre, S., Markovits, J., Couprie, J., Jacquemin-Sablon, A. and Larsen, A. K. (1992) Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells. Proc. Natl. Acad. Sci. U.S.A.. 89, 3025-3029.
  131. Khaled, Z., Rideout, D., O'Driscoll, K. R., Petrylak, D., Cacace, A., Patel, R., Chiang, L.-C., Rotenberg, S. and Stein, C. A. (1995) Effects of suramin-related and other clinically therapeutic polyanions on protein kinase C activity. Clin. Cancer Res. 1, 113-122.
  132. Kopp, R. and Pfeiffer, A. (1990) Suramin alters phosphoinositide synthesis and inhibits growth factor receptor binding in HT-29 cells. Cancer Res. 50, 6490-6496.
  133. Spigelman, Z., Dowers, A., Kennedy, S., DiSorbo, D., O'Brien, M., Barr, R. and McCaffrey, R. (1987) Anti-proliferative effects of suramin on lymphoid cells. Cancer Res. 47, 4694-4698.
  134. Nakajima, M., DeChavigny, A., Johnson, C. E., Hamada J., Stein, C. A. and Nicolson, G. L. (1991) Suramin. A potent inhibitor of melanoma heparanase and invasion. J. Biol. Chem. 266, 9661-9666.
  135. Behrendt, N., Ronne, E. and Dano, K. (1993) Binding of urokinase-type plasminogen activator to its cell surface receptors is inhibited by low doses of suramin. J. Biol. Chem. 268, 5985-5989.
  136. Zabrenetzky, V. S., Kohn, E. C. and Roberts, D. D. (1990) Suramin inhibits laminin- and thrombospondin-mediated melanoma cell adhesion and migration and binding to these adhesive proteins. Cancer Res. 50, 5937-5942.
  137. Sola F., Farao, M., Marsiglio, A., Mariani, M. and Grandi, M. (1993) Inhibition of lung and liver tumor colonies in mice pretreated with suramin. Invasion Metastasis 13, 163-168.
  138. Pesenti, E., Sola, F., Mongelli, N., Grandi, M. and Spreafico, F. (1992) Suramin prevents neovascularization and tumor growth through blocking of basic fibroblast growth factor activity. Br. J. Cancer 66, 367-372.
  139. Collins, J. M., Klecker, R. W., Yarchoan, R., Lane, H. C., Fauci, A. S., Redfield, R. R., Broder, S. and Myers, C. E. (1986) Clinical pharmaco-kinetics of suramin in patients with HTLV-III/LAV infection. J. Clin. Pharmacol. 26, 22-26.
  140. Constantopoulos, G., Ress, S., Cragg, B. G., Barranger, J.A. and Brady, R. O. (1983) Suramin-induced storage disease. Mucopolysaccharidosis. Am. J. Pathol. 113, 266-268.
  141. Fan, T.-P., Jaggar, R. and Bicknell, R. (1995) Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol. Sci. 16, 57-66.
  142. Takano, S., Gately, S., Neville, M. E., Herblin, W. F., Gross, J. L., Engelhard, H., Perricone, M., Eidsvoog, K. and Brem, S. (1994) Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator. Cancer Res. 54, 2654-2660.
  143. Ciomei, M., Pastori, W., Mariani, M., Sola, F., Grandi, M. and Mongelli, N. (1994) New sulfonated distamycin A derivatives with bFGF complexing activity. Biochem. Pharmacol. 47, 295-302.
  144. Sola, F., Farao, M., Pesenti, E., Marsiglio, A., Mongelli, N. and Grandi, M. (1995) Antitumor activity of FCE 26644 a new growth-factor complexing molecule. Cancer Chemother. Pharmacol. 36, 217-222.
  145. Zugmaier, G., Lippman, M. E. and Wellstein, A. (1992) Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J. Natl. Cancer Inst. 84, 1716-1724.
  146. Belford, D. A., Hendry, I. A. and Parish, C. R. (1993) Investigation on the ability of several naturally occurring and synthetic polyanions to bind to and potentiate the biological activity of acidic fibroblast growth factor. J. Cell. Physiol. 157, 184-189.
  147. Wellstein, A., Zugmaier, G., Califano, J.A., Kern, F., Paik, S. and Lippman, M. E. (1991) Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J. Natl. Cancer Inst. 83, 716-720.
  148. McLeskey, S. W., Zhang, L., Trock, B. J., Kharbanda, S., Liu, Y., Gottardis, M. M., Lippman, M. E. and Kern, F. G. (1996) Effects of AGM-1470 and pentosan polysulphate on tumorigenicity and metastasis of FGF-transfected MCF-7 cells. Br. J. Cancer 73, 1053-1062.
  149. Baba, M., Nakajima, M., Schols, D., Pauwels, R., Balzarini, J. And De Clercq, E. (1988) Pentosan polysulfate, a sulfated oligosaccharide, is a potent and selective anti-HIV agent in vitro. Antiviral Res. 9, 335-343.
  150. Parker, B. W., Swain, S. M., Zugmaier, G., DeLap, R. L., Lippman, M. E. and Wellstein, A. (1993) Detectable inhibition of heparin-binding growth factor activity in sera from patients treated with pentosan polysulfate. J. Natl. Cancer Inst. 85, 1068-1073.
  151. Pluda, J. M., Shay, L. E., Foli, A., Tannenbaum, S., Cohen, P. J., Goldspiel, B. R., Adamo, D., Cooper, M. R., Broder, S. and Yarchoan, R. (1993) Administration of pentosan polysulfate to patients with human immunodeficiency virus associated Kaposi's sarcoma. J. Natl. Cancer Inst. 85, 1585-1592.
  152. Foxall, C., Wei, Z., Schaefer, M. E., Casabonne, M., Fugedi, P., Peto, C., Castellot, J. J. and Brandley, B. K. (1996) Sulfated malto-oligosaccharides bind to basic FGF, inhibit endothelial cell proliferation, and disrupt endothelial cell tube formation. J. Cell. Physiol. 168, 657-667.
  153. Saiki, I., Murata, J., Nakajima, M., Tokura, S. and Azuma, I. (1990) Inhibition of by sulfated chitin derivatives of invasion through extracellular matrix and enzymatic degradation by metastatic melanoma cells. Cancer Res. 50, 3631-3637.
  154. Murata, J., Saiki, I., Makabe, T., Tsuta, Y., Tokura, S. and Azuma, I. (1991) Inhibition of tumor-induced angiogenesis by sulfated chitin derivatives. Cancer Res. 51, 22-26.
  155. Li, W. W., Casey, R., Gonzalez, E. M. and Folman, J. (1991) Angiostatic steroids potentiated by sulfated cyclodextrins inhibit corneal neovascularization. Invest. Ophthalmol. Visual Sci. 32, 2898-2905.
  156. Thorpe, P. E., Derbyshire, E. J., Andreade, S. P., Press, N., Knowles, P. P., King, S., Watson, G. J., Yang, Y.-C. and Rao-Betté, M. (1993) Heparin-steroid conjugates: new angiogenesis inhibitors with antitumor activity in mice. Cancer Res. 53, 3000-3007.
  157. Folkman, J., Langer, R., Linhardt, R. J., Haudenschild, C. and Taylor, S. (1983) Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 221, 719-725.
  158. Crum, R., Szabo, S. and Folkman, J. (1985) A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 230,1375-1378.
  159. Ingber, D. E., Madri, J. A. and Folkman, J. (1986) A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology 119, 1768-1775.
  160. Guvakova, M. A., Yakubov, L. A., Vlodavsky, I., Tonkinson, J. L. and Stein C. A. (1995) Phosphotothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors, and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem. 270, 2620-2627.
  161. Fennewald, S. M. and Rando, R. F. (1995) Inibition of high affinity basic fibroblast growth factor binding by oligonucleotides. J. Biol. Chem. 270, 21718-21721.
  162. Benimetskaya, L., Tonkinson, J. L., Koziolkiewicz, M., Karwowski, B., Guga, P., Zeltser, R., Stec, W. and Stein, C. A. (1995) Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is P-chirality independent. Nucleic Acids Res. 23, 4239-4245.
  163. Jellinek, D., Lynott, C. K., Rifkin, D. B. and Janjic, N. (1993) High-affinity RNA ligands to basic fibroblast growth factor inhibit receptor binding. Proc. Natl. Acad. Sci. U.S.A. 90, 11227-11231.
  164. Peters, T. and Pinto, B. M. (1996) Structure and dynamics of oligosaccharides: NMR and modeling studies. Curr. Opin. Struct. Biol. 6, 710-720.